Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Narrative) (Details)

v3.22.2.2
Revenues from Contracts and Significant Customers (Narrative) (Details)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
customer
Sep. 30, 2021
customer
Sep. 30, 2022
USD ($)
customer
Sep. 30, 2021
customer
Dec. 31, 2021
customer
Dermira, Inc. a subsidiary of Eli Lilly [Member]          
Disaggregation of Revenue [Line Items]          
Payments of milestones | $     $ 7.5    
Journey [Member]          
Disaggregation of Revenue [Line Items]          
Payments of milestones | $     $ 10.0    
Dermatology Products Sales [Member] | Customer Concentration Risk [Member] | Revenue [Member]          
Disaggregation of Revenue [Line Items]          
Number of customers 0   0 0  
Dermatology Products Sales [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Number of customers     2   2
Dermatology Products Sales [Member] | One Customer [Member] | Customer Concentration Risk [Member] | Revenue [Member]          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage   10.10%      
Number of customers   1      
Dermatology Products Sales [Member] | Customer one [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage     17.00%   11.00%
Dermatology Products Sales [Member] | Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Disaggregation of Revenue [Line Items]          
Concentration risk, percentage     16.00%   13.00%